Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Stroke. 2022 Oct 20;53(12):3769–3779. doi: 10.1161/STROKEAHA.122.038585

Figure 1:

Figure 1:

Diagram of molecular pathways which are likely hyper-activated by SWS somatic mutation in the protein Gαq. This figure also indicates several classes of inhibitors, including mTOR inhibitor such as Sirolimus, which are being tested, or may be studied in future clinical drug trials for SWS.